Mitapivat is a medication being studied for its potential effects on sickle cell disease. It works by activating an enzyme in red blood cells, which can help them function better. In this trial, researchers are looking at how mitapivat might improve blood flow and oxygen use in the brain for people with sickle cell disease. This could potentially help reduce some of the complications associated with the disease, such as pain and organ damage. The goal is to see if mitapivat can make a positive difference in the way the brain receives and uses oxygen in patients with this condition.

Sickle Cell Anemia – Sickle cell anemia is a genetic blood disorder characterized by the production of abnormal hemoglobin, known as hemoglobin S. This causes red blood cells to become rigid, sticky, and shaped like sickles or crescent moons. These misshapen cells can block blood flow, leading to pain and potential organ damage. Over time, the disease can cause anemia, as the sickle cells break down prematurely. The condition can also lead to episodes of pain, known as sickle cell crises, which occur when blood flow is obstructed. Chronic complications may include damage to organs such as the spleen, liver, and kidneys.